As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
31 Analysts have issued a Novo Nordisk forecast:
31 Analysts have issued a Novo Nordisk forecast:
Jun '25 |
+/-
%
|
||
Revenue | 311,938 311,938 |
21%
21%
|
|
Gross Profit | 261,870 261,870 |
20%
20%
|
|
EBITDA | 158,810 158,810 |
18%
18%
|
EBIT (Operating Income) EBIT | 142,799 142,799 |
22%
22%
|
Net Profit | 111,068 111,068 |
24%
24%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Head office | Denmark |
CEO | Lars Jørgensen |
Employees | 76,826 |
Founded | 1931 |
Website | www.novonordisk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.